INTRODUCTION
The purpose of this project entitled "Ethanol and mesolimbic serotonin (5-I-T)/dopamine (DA) interactions via 5-HT-1B receptors" is to investigate whether activation of 5-HT-lB receptors within the ventral tegmental area (VTA) facilitates DA transmission in the ipsilateral nucleus accumbens (NACC) and potentiates ethanol-induced increases in NACC DA by 5-HT-lB receptor-mediated GABA mechanisms. The scope of this project covers the following specific aims: (1) To determine the involvement of 5-IHT-lB heteroreceptors on GABA terminals in the VTA in the modulation of GABA release in the VTA and DA release in the ipsilateral NACC, and its involvement in the neurochemical effect of acute ethanol in freely moving animals; (2) To compare the impact of 5-I-T-lB receptor activation on DA transmission in the NACC and on ethanol's neurochemical effects between 5-I-T-lB receptor knock-out (KO) mice and their counterparts wild-type (WT) mice, (3) To determine the involvement of 5-IIT-LB heteroreceptors on GABA terminals in the VTA in the modulation of DA and GABA releases in the VTA, and its involvement in the effect of ethanol in superfused VTA slices.
BODY Specific Aim 1: To determine the involvement of 5-HT-1B heteroreceptors on GABA terminals in the VTA in the modulation of GABA release in the VTA and DA release in the ipsilateral NACC, and its involvement in the neurochemical effect of acute ethanol in freely moving animals There are two hypotheses under Specific Aim 1: (1) Activation of 5-HT-1B receptors in the VTA decreases GABA release in this area and increases DA transmission in the ipsilateral NACC and (2) Activation and blockade of VTA 5-HT-lB receptors potentiates and attenuates ethanol's effects on DA transmission in the ipsilateral NACC, respectively. According to Statement of Work, experiments under Specific Aim 1 are to be completed in two years.
The experiments related to the first hypothesis of Specific Aim 1 were completed in Year 2. The data reported in the second annual report have already been published in Brain Research (1021: 82-91, 2004, please see the appendices). The experiments related to the second hypothesis were continued and have been completed during the third year of the project. The following data were obtained in Year 3 and have not been reported in the previous reports.
1. Effects of acute ethanol on extracellular DA and GABA in the VTA and DA in the ipsilateral NACC. In these experiments, dual-probe microdialysis was used in adult male Sprague-Dawley rats as described previously 1 . One probe was inserted into the VTA and the other in the ipsilateral NACC. Both probes were perfused with artificial cerebrospinal fluid (ACSF) at the rate of 1.5 -2.0 Al/min. The dialysates from the VTA and NACC were collected at 20 min of intervals, and assayed via the HPLC-EC (high performance liquid chromatography coupled with electrochemical detection) system for DA in the NACC, and GABA and DA in the VTA (The VTA dialysates were divided into two portions: one for GABA assay and the other for DA measurement). After the release of transmitters in the VTA and NACC was stable, ethanol (1 and 2 g/kg) or saline was injected ip and microdialysis was continued for another 2 h. These experiments were necessary for this laboratory to establish our own effective doses of ethanol. Time (min)
The basal values (fmol/sample) of extracellular DA in the VTA and NACC were: 9.04 ± 1.32 and 29.09 ± 3.09 (the saline group, n = 6), 10.99 ± 1.04 and 34.39 ± 2.72 (the 1 g/kg ethanol group, n = 7), and 8.94 ± 0.72 and 28.24 ± 2.30 (the 2 g/kg ethanol group, n = 7), respectively. There were no statistically significant differences in basal DA in the VTA or the NACC among the ethanol and saline groups. As shown in Figs 1 and 2, intraperitoneal injection of saline had no significant effects on dialysate levels of DA from either the VTA or the ipsilateral NACC. However, administration of ethanol at the doses of 1 and 2 g/kg increased extracellular DA concentrations by -38% and -56% of baseline in the VTA, and -51% and -67% of baseline in the NACC, respectively. The maximum increases in DA release in the VTA were temporally correlated with those in the NACC after administration of ethanol at both doses. These data are consistent with the previous studies carried out in this2 and other 3 ' 4 laboratories showing that acute ethanol increased terminal or somatodendritic DA release in separate animals. Moreover, the present experiments, by taking advantages of simultaneous measurements of DA release in both the VTA and NACC in the same animals, extend these findings to show that ethanol-induced increases in somatodendritic and axon terminal DA release are correlative temporally and similar in magnitude. Simultaneous demonstration of both somatodendritic and axon terminal DA release in the same animals may provide more complete profiles regarding the effects of ethanol on the mesolimbic DA pathway. The observed similarity in the time course of DA between cell body and terminal areas after ethanol is opposite to that observed with cocaine which increases extracellular DA by a different mechanism. The previous study carried out in this laboratory showed that systemic cocaine produced different DA time courses in the VTA and the NACC with much 12 longer increases in the former than in the latter , and 169.85 ± 10.08 (the 2 g/kg ethanol group, n = 7). There were no statistically significant differences in the basal GABA levels among the ethanol and saline groups. As shown in this figure, administration of ethanol at the doses of 1 or 2 g/kg did not cause any significant changes in dialysate GABA levels as compared with the saline group, suggesting that acute ethanol may not affect extracellular GABA in the VTA under the present experimental conditions. Cowen et al. 5 also reported that administration of ethanol (1 g) by gavage had no significant effects on extracellular GABA in the VTA or the substantia nigra. However, it must be remembered that the technique of in vivo microdialysis requires long sampling time due to the low flow rates employed, and as such can only readily quantify substantial changes in release of neurotransmitters that are maintained for a period of time. It is possible that acute ethanol administration evoked a transient change in GABA release in the VTA that was masked in a 20-min sample. In addition, as mentioned in the grant application, part of GABA collected by microdialysis probes may originate from nonneuronal stores 6 . Therefore, it is also possible that potential alterations in exocytotic GABA release resulting from ethanol administration may only cause a small change in total extracellular GABA levels that cannot be detected by our HPLC system. Regardless of the explanations, an inability to detect measurable changes in the release of endogenous GABA in the VTA following ethanol does not necessarily mean that VTA GABA is not a target of acute ethanol. Further studies using different techniques to detect ethanol's effects on the GABA system in the VTA may be needed. Since no measurable changes in VTA dialysate GABA were detected after administration of ethanol at the doses of 1 or 2 g/kg, attention were paid to VTA DA and NACC DA in the following experiments.
2. The effects of infusion of a 5-HT-1B receptor antagonist into the VTA on ethanol-induced DA release in this region and in the ipsilateral NACC. Dual-probe microdialysis was employed the same as above except that a 5-HT-1 receptor antagonist was infused into the VTA 20 minutes before ethanol until the end of the experiments. In these experiments, the following antagonists were used: SB 216641, a 5-HT-lB receptor antagonist, BRL 15572, a 5-HT-iD/lA receptor antagonist 7 , and WAY 100635, a 5-HT-lA receptor antagonist 8 . The affinities (given as pKi) of these antagonists for related 5-IHT-1 receptor subtypes are listed in the following table. All these antagonists were infused into the VTA at the concentration of 10 jiM in ACSF. The previous results showed that infusion of SB 216641, but not BRL 15572 or WAY 100635, at this concentration antagonized not only the effects of intrategmental CP 93129 on VTA DA and NACC DA but also on VTA GABA 1 , suggesting that 10 jiM of SB 216641 was sufficient to block VTA 5-HT-1B receptors. The previous studies also showed that infusion of SB 216641, WAY 100635, or BRL 15572 at the concentration of 10 jiM into the VTA for 2 h did not significantly alter extracellular DA levels in either the VTA or the ipsilateral NACC 1 .
Compound
Receptor subtype (pKi) 5-HIT-A 5-HT-lB 5-HT-1D SB-216641 6.3 9.0 7.6 BRL-15572 7.7 6.1 7.9 WAY-100635 8.9 < 6 < 6 3. Effects of infusion of CP 94253 into the VTA on ethanol (1 and 2 g/kg)-induced DA release in the ipsilateral NACC. Dual-probe microdialysis was employed the same as above except that CP 94253 (10 g•M) was infused into the VTA 20 minutes before ethanol injection until the end of the experiments. CP 94253 was chosen because it has been found to have at least a 40-fold and a 20-fold greater selectivities for the 5-HT-1B receptor over the 5-HT-1A and the 5-HT-1D receptor, respectively (Ki values are 89, 2, 860, 49 and 1600 nM for 5-HT-1A, 5-HT-1B, 5-HT-1C, 5-HT-1D and 5-HT-2 receptors, respectively) 11 . In addition, CP 94253 has an advantage over CP 93129, which by itself can produce a peak under our experimental conditions that may sometimes interfere with the peak of DA. These experiments were designed to investigate further the involvement of VTA 5-HT-1B receptors in modulation of the effects of ethanol on DA release in the NACC. In a group of rats, infusion of 10 gM of CP 94253 into the VTA for 140 min did not significantly alter extracellular DA levels in the ipsilateral NACC. The previous study also showed that infusion of CP 93129 into the VTA at the concentration of 20 gM did not significantly change extracellular DA in the ipsilateral NACC1. As shown in Figs 8 and 9, co-administration of CP 94253 significantly prolonged the effects of ethanol (1 and 2 g/kg) on the extracellular DA in the NACC although the maximum increases of NACC DA after co-administration of CP 94253 and ethanol did not significantly differ from those after administration of ethanol alone. In the absence of CP 94253, extracellular DA in the NACC was increased rapidly to the maximum level after administration of ethanol at the doses of 1 (Fig 8) and 2 g/kg (Fig 9) , then declined gradually and reached the control level at 80 min after ethanol injection. However, in the presence of CP 94253, extracellular DA still remained significantly high levels as compared with either the saline or ethanol alone group at 80 -120 min after administration of ethanol at the both doses (Figs 8 and 9 ). As stated in the second annual report, due to a spread of mouse hepatitis virus at the vivarium of Dr. Rene Hen, a professor of Columbia University, who originally promised me to provide the KO and WT mice, I cannot obtain these animals directly from Dr. Hen. As a result, the work related to breeding of the KO and WT mice and genotyping of these animals were successfully developed at my laboratories during Year 2. However, breeding and genotyping substantially increased our workload, and consequently have impacts on the speed of the progress of the project. ). There were no statistically significant differences in the basal DA values between the KO and WT mice. As compared with saline injections, administration of RU 24969 did not produce significant changes in extracellular NACC DA concentrations in the KO mice (Panel A of Fig 10) , but did so in the WT mice (Panel B of Fig 10) . After RU 24969 administration, extracellular NACC DA concentrations were significantly higher at the time points of 60 -140 min in the WT mice than those in the KO mice (panel C of Fig  10) . The previous studies have shown that activation of 5-HT-1B receptors within the VTA increases DA release in the ipsilateral NACC in rats 1 . The present data showing that RU 24969 increased NACC DA in the WT but not in the 5-HT-1B receptor KO mice further support the notion that activation of 5-HT-1B receptors facilitates DA transmission in the mesolimbic DA pathway.
The other experiments under Specific Aim 2 are currently in progress. As mentioned in the previous annual reports, due to a delay in hiring the post-doctoral research associate in Year 1 and an unforeseen increase in workload resulting from breeding and genotyping of KO and WT mice in Years 2 and 3, the progress in the project has considerably lagged behind the originally proposed schedule. As a result, the PI may apply for a one-year no-cost extension. [22] , and found to be easily distinguished from those of minimize the effects of the compounds on the structures VTA DA neurons. These VTA GABA neurons are other than the VTA. The effects of the drugs on extracellular presumed to modulate mesolimbic DA neuronal activity DA and GABA levels in the VTA and DA levels in the in a manner similar to the inhibition of nigrostriatal DA NACC were measured simultaneously. neurotransmission by substantia nigra pars reticulata GABA neurons [54] .
It has been reported that 5-HTIB receptors are 2. Materials and methods predominantly located on axon terminals [4, 51] . In keeping with this localization, 5-HTm receptors have been 2.1. Animals shown to regulate neurotransmitter release from nerve terminals. Activation of 5-HT 1 B autoreceptors on seroto-Male Sprague-Dawley rats, weighing 250-300 g at the nergic terminals resulted in inhibition of 5-HT release in time of surgery, were obtained from Harlan Spraguethe frontal cortex [19] , hippocampus [50] , and striatum Dawley (Indianapolis, IN, USA) . They were housed at [1] . Using electrophysiological techniques, Mlinar et al.
21±3 'C, 40-60% relative humidity and were maintained [37, 38] demonstrated that 5-HTm receptors were responunder 12-h light/12-h dark conditions with ad libitum access sible for the presynaptic inhibition of neurotransmission in to food and water. All animal care and experimentation were the CAI region of the hippocampus. It has also been carried out in accordance with the NIH Guide for the Care reported that 5-HTIB receptors can function as a hetero-and Use of Laboratory Animals and were approved by the receptor in some brain areas to inhibit releases of Institutional Animal Care and Use Committee of the glutamate [3] , GABA [12, 63] or acetylcholine [11] .
University of Illinois College of Medicine at Peoria. Interestingly, recent studies showed that, in addition to 5-HTIA receptors, 5-HT release in rat dorsal and median 2.2. Drugs raphe nuclei was also controlled by 5-HTm autoreceptors [28] [7] . Using intracellular recording phenyl]-2' -methyl-4' -(5-methyl-1,2,4-oxadiazol-3-yl)from midbrain DA neurons in a brain slice containing the [1,1' -biphenyl]-4-carboxamide hydrochloride) was VTA, Cameron and Williams [8, 9] found that activation obtained from Tocris (Ellisville, MO, USA). CP 93129 of 5-HIm receptors in the VTA by sumatriptan resulted {3-(1,2,5,6-tetrahydro-4-pyridyl)pyrrolo [3, 2] pyrid-5-one} in reductions of the magnitude of GABA-mediated was generously provided by Pfizer (Groton, CT, USA). All inhibitory post-synaptic potential, suggesting that VTA drugs were dissolved in water and then diluted to desired 5-HTIB receptors may be involved in modulation of concentrations with artificial cerebrospinal fluid (ACSF) GABA input into VTA DA neurons although the potential before administration. Other reagents used were of analytinvolvement of 5-HTID receptors cannot be ruled out. Our ical grade. previous studies also showed that activation of 5-HTIB receptors inhibited high potassium-evoked [ 3 H]GABA 2.3. Microdialysis release from the VTA slices, supporting the hypothesis that 5-HT 1 B receptors within the VTA can function as
The animals were prepared for the microdialysis experiheteroreceptors to decrease GABA release in this region ments as described in a previous paper [64] . In brief, surgery [63]. However, these studies were all performed in vitro, was conducted on a Kopf stereotaxic instrument under At present, direct in vivo evidence supporting the anesthesia with a combination of sodium pentobarbital (35 involvement of VTA 5-HTIB receptors in the regulation mg/kg, i.p.) and halothane (5% in oxygen). Dialysis guide of mesolimbic DA neuronal activities via GABA mech-cannulae (Harvard Apparatus, S. Natick, MA, USA) were anisms is lacking. stereotaxically implanted over both the VTA and the The present study was designed to address this issue by ipsilateral NACC and attached to the skull with dental investigating the role of VTA 5-HT 1 B receptors for the acrylic and machine screws. The coordinates relative to modulation of DA and GABA release in the VTA and DA bregma and skull surface were as follows: the VTA: AP release in the ipsilateral NACC in the same animals. [46] . The period of post-using a computer-based data acquisition system (EZChrom surgical recovery was at least 5 days. On the evening of the Chromatography Data System, Scientific Software, San day before the experiment, each rat was placed in a plexiglas Ramon, CA, USA). The detection limit for dopamine was chamber and dialysis probes (1 and 2 mm in length for the -4 fmol at a 2:1 signal-to-noise ratio. VTA and NACC, respectively), made from cellulose acetate For determination of GABA, an isocratic HPLC system hollow fibers (I. D. 215±15 gsm, molecular weight cut-with electrochemical detection was used. This system off=-6000; Spectrum Medical Industries, Los Angeles, CA, consisted of an ESA solvent delivery system (model 580), USA), were inserted while gently restraining the freely an ESA autosampler (Model 542), a Waters Xterra TM MS behaving rat. On the experimental day, ACSF, which column (50x3 umm, C18, 2.5 1 tM), and an ESA coulochem contained (in mM) Na+ (150), K+ (3.0), Ca2+ (1.2), Mg 2 + III electrochemical detector equipped with an analytical cell (0.8), C1-(155), was perfused at 2 il/min. After 3-4 h, (Model 5011) and a guard cell (Model 5020). The guard cell dialysate samples from both the VTA and NACC were was set at 650 mV, and the analytical cell at 250 mV (El) collected at 20-min intervals into vials containing 5 ptl 0.1 N and 550 mV (E2). The mobile phase contained 100 mM HC1, and stored at -80 'C until analysis. Dialysate samples Na 2 HPO 4 , 0.13 mM Na 2 EDTA and 28% methanol (pH 6.4 from the VTA were divided into two portions with one with H 3 PO 4 ), and was pumped through the system at 0.5 ml/ portion for measurements of DA and the other for min. Pre-column derivatization with o-phthaldialdehyde determinations of GABA. Frozen samples showed no signs (OPA)/2-mercaptoethanol was performed automatically by of degradation for up to 1 month in our previous studies the autosampler by mixing 15 [tl of the working derivatizing [61, 62, 64] . All treatments were administered via a dialysis reagent with 20 il of dialysate samples or working standard probe.
solutions for 2 min. The detection limit for GABA was -50 In order to evaluate the implantation of the probe pg at a 2:1 signal-to-noise ratio. functionally, each dual-probe experiment was finished with After completion of the dialysis, the animals were given infusion of 50 [tM of baclofen, a GABAB receptor agonist, an intracardiac perfusion with buffered saline and 10% into the VTA probe and the response of extracellular DA in formalin solutions under anesthesia with sodium pentobarthe ipsilateral NACC was determined. A significant bital, and then decapitated. The brains were removed decrease (_>50% deduction) in extracellular DA in the quickly, and 40-[tm-thick coronal sections were cut on a ipsilateral NACC after perfusion with baclofen was consid-freezing microtome, stained with neutral red and analyzed in ered an appropriate implantation of the probe.
the light microscope. The heavy staining of gliosis along the guide cannula track permitted reliable location of the 2.4. Analytical and histological procedure deepest point of penetration. A 2-mm-long (in the NACC) or 1-mm-long (in the VTA) dialysis membrane extended For measurement of DA, dialysate samples were injected below the tip of the guide cannula. The point of the probe onto a high performance liquid chromatography (HPLC) tip was then marked on coronal sections from the atlas of system with electrochemical detection. This system con-Paxinos and Watson [46] . sisted of an ESA solvent delivery system (model 580), an ESA microbore column (MD-150x 1/RP-C18, 3 [M) for the 2.5. Data analysis VTA samples or an ESA narrowbore column (MD-150x2/ RP-C18, 3 itM) for the NACC samples, and an ESA All values of DA and GABA reported herein represented coulochem II electrochemical detector equipped with a dual uncorrected dialysate levels and were expressed as fmol/ electrode analytical cell (Model 5041) and a guard cell sample. The volume of the sample for determination of VTA (Model 5020). The guard cell was set at 400 mV, electrode DA, NACC DA, and VTA GABA was 5, 20, and 20 ltl, at 175-200 mV with respect to palladium reference respectively. A two-way analysis of variance (ANOVA) electrodes. A VICI micro-electric two-position valve actua-followed by Tukey's tests was applied. All analyses were tor with a 5-[d (for the microbore column) or 50-pl (for the performed through computer-based software (SigmaStat). narrowbore column) injection loop was used for sample The criterion of significance was set at P<0.05. injection. For VTA DA determination, 10-pl dialysate samples were injected to ensure that the 5-ptA injection loop was completely filled, For NACC DA assay, 20-itl dialysate 3. Results samples were injected onto the column. The mobile phase contained 75 mM Na 2 HPO 4 , 1.53 mM sodium dodecyl Only data from animals with correct probe placements sulfate, 25 giM EDTA, 100 gtl/1 triethylamine, 11.5% and appropriate accumbal DA responses to perfusion of the acetonitrile and 11.5% methanol (pH 5.6 with H 3 PO 4 ), VTA with baclofen were included in data analyses. and was pumped through the system at 0.07 (for the Approximately 75% of the animals that had undergone microbore column) or 0.25 (for the narrowbore column) ml/ surgery had both probes correctly implanted in the VTA and min. Chromatograms were integrated, compared with stand-NACC, and met the functional criterion. 
Effects of infusion of CP 93129 into the VTA on 100--e-0 RM
---20 gM extracellular DA concentrations in this region (Fig. 1) and
40 gM in the ipsilateral NACC (Fig. 2) + 80 80 M +8*0---80-E Three concentrations of CP 93129 (20, 40 and 80 [M) were administered via a probe into the VTA of three groups 60\ 0 of rats for 60 min, respectively, and extracellular levels of DA in both regions were monitored simultaneously. In 40 0-
. .another group of rats (the control group), ACSF was infused . into the VTA for the same period as the drug groups and . switching between syringes containing ACSF in this group 0 20. was found to have no significant effects on the dialysate DA CP 93129 levels in the VTA (Fig. 1 ) or in the ipsilateral NACC ( (Fig. 1) , and 160%, 181%, as compared with the 20-gM group (two-way ANOVA followed by Tukey's 217% of baseline in the NACC (Fig. 2) , respectively. The tests). effects of 20 gM of CP 93129 on VTA DA did not reach statistical significance when compared with the control concentration of 20 or 40 gM did not produce significant group.
alterations in the level of VTA GABA either when compared with the control group although there were 3.2. Effects of infusion of CP 93129 into the VTA on tendencies towards reductions following drug infusion. extracellular GABA concentrations in this region (Fig. 3) However, infusion of CP 93129 at the concentration of 80 [tM caused extracellular GABA in the VTA to decrease by As shown in Fig. 3 , infusion of ACSF alone (the control 37% of baseline (P=0.043 and P=0.04 at 20 and 60 min group) did not cause significant changes in GABA levels after drug application, respectively). Upon comparing the from VTA dialysates. Administration of CP 93129 at the time course of VTA GABA with that of VTA DA or NACC outputs in the VTA (Fig. 4) and NACC (Fig. 5 ) were all 16 significantly lower than those in the absence of SB 216641 0(P<0.05, two-way ANOVA followed by Tukey's tests (Fig. 4 ) and the ipsilateral NACC (Fig. 5 In these experiments, WAY 100635 (a 5-HTlA receptor -80 antagonist), SB 216641 (a 5-HTtB receptor antagonist), and E BRL 15572 (a 5-HT1D/IA receptor antagonist) were used. M All these drugs were infused into the VTA at the Z concentration of 10 gM for 40 min alone and then coinfused with CP 93129 (80 gM) for another 60 min, E 40. respectively. The concentration of antagonists was chosen E based on the reports in the literature and -5% of the 0. efficiency of the probe used. It has been shown that 10-100 0 20 nM of WAY 100635 potently antagonized the 5 VTA for 2 h did not significantly alter extracellular DA levels C 1000.
The present in vivo study shows that local application of CP 93129, a 5-HTiB receptor agonist, into the VTA increased not only somatodendritic DA release in this region but also DA release from nerve terminals in the 0 _ NACC, consistent with the excitation of mesolimbic DA 0 20 40 60 neurons. CP 93129 is a putatively specific 5-HTtB receptor Time (min) after CP 93129 addition agonist, with :> 150-fold higher affinity for 5-HTIB vs. other Fig. 6 . Comparisons of CP 93129-induced decreases of extracellular VTA 5-HT 1 and 5-HT 2 ligand binding sites (IC 50 values: 5-HTlA GABA in the presence and absence of WAY-100635, SB 216641, or BRL 3000±400, 5-HTin 15_±5, 5-HTlD 2200±700, and 5-HT 2 > 15572. WAY-100635 (10 gM), SB 216641 (10 gM), and BRL 15572 (10 10,000 nM) [17, 35] . It is also claimed to lack substantial gM) were administered through the probe into the VTA for 40 min, and affinity for dopamine, noradrenaline or opiate receptors then co-infused with CP 93129 (80 jtM) for another 60 min, respectively.
[35]. The concentrations of CP 93129 used in this study Results are mean±_S.E.M. from six to seven animals. The data of the group were 20-80 gM. Considering approximately -5% of the of CP 93129 (80 giM) alone were obtained from Fig. 3 . *P<0.05 as compared with the group of CP 93129 alone (two-way ANOVA followed efficiency of the probe used in the VTA, it is estimated that by Tukey's tests).
actual concentrations of CP 93129 in the extracellular fluid immediately adjacent to the dialysis membrane may be in 45% of baseline (data not shown). The observed effects of the range of 1-4 [iM. This poses the possibility that the baclofen on NACC DA were consistent with those reported selectivity of CP 93129 for the 5-HTin receptors may have in the literature [57, 67] , suggesting the functional integrity been compromised. Although this possibility cannot be of the circuitry studied in our dual-probe design.
ruled out, two aspects of the dialysis .technology may require the high concentrations. First, the rate constant of diffusion of compounds from the perfusion medium into the 4. Discussion brain may be high enough that higher concentrations in the perfusate are necessary to maintain concentrations in the The DA release in both somatodendritic (VTA) and axon neuropil; these concentrations can be achieved at lower terminal areas (NACC) were simultaneously determined in levels in in vitro preparations where a significant diffusion this study. Previous studies show that, in addition to barrier is not present. Second, in addition to diffusion across classical DA release from synapses in their terminal areas, the dialysis membrane, a concentration gradient away from VTA DA neurons release DA from their somata and the probe surface into the neuropil will exist. Thus, to dendrites [15, 30] . Microdialysis findings have shown that, achieve pharmacologically active concentrations in the similar to extracellular DA in the NACC, extracellular DA neuropil not adjacent to the dialysis membrane it may be in the VTA was tetrodotoxin sensitive and calcium dependnecessary to have higher drug concentrations in the tissue ent [10, 13, 32 ], suggesting that a depolarization-induced, adjacent to the probe. exocytosis-mediated, somatodendritic release of DA To assess the involvement of 5-HTIB receptors in CP occurred in the VTA under basal conditions. Evidence also 93129's actions, WAY-100635 (a 5-HT1A receptor antagoindicated that extracellular DA in the VTA was regulated by nist) [21] , SB 216641 (a 5-HT 1 B receptor antagonist) D2 autoreceptors and DA reuptake processes [14, 32] . Taken [26, 48] , and BRL 15572 (a 5-HT1D/1A receptor antagonist) together, the data suggest that somatodendritic DA in the [26, 48] were used. The affinities (given as pKi) of these VTA, like that released from axon terminals in the NACC, antagonists for 5-HT-1A,-1B, and-lD receptor subtypes are as was also dependent on the neuronal firing rate and thus can follows: WAY 100635: 8.9, <6, and <6; SB 216641: 6.3, be used as an index of the activity of mesolimbic DA 9.0, and 7.6; BRL 15572: 7.7, 6.1, and 7.9 [26, 48] . All these neurons. Drugs that increase the firing rate of mesolimbic drugs were tested for their impacts on the actions of CP DA neurons increase the extracellular DA levels in both the 93129 at a highest concentration used, i.e., 80 gM, since, VTA and the NACC when they are focally applied into the theoretically, higher concentrations of CP 93129 would have VTA. For example, intra-tegmental administration of less selectivity as compared with lower concentrations. If 5nicotine, a drug that increases mesolimbic DA transmission HTIA receptors are involved in the actions of CP 93129, by augmentations of DA neuronal firing rates [36, 41] , WAY 100635 (pKi=8.9 for the 5-HTlA receptor) and BRL
